Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.

• Publication year

  2015

• Venue

  Neuropsychiatric Disease and Treatment

• Publication date

  2015-11-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/NDT.S87359PMID 26640376PMCID 4657797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice

  2013cited by this paper
• Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version

  2011cited by this paper
• Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity

  2011cited by this paper
• Toward a New Understanding of Attention-Deficit Hyperactivity Disorder Pathophysiology

  2009cited by this paper
• New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD.

  2008cited by this paper
• Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder

  2006cited by this paper
• Molecular genetics of attention-deficit/hyperactivity disorder.

  2005cited by this paper
• Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment

  2000cited by this paper
• Clinical Ophthalmology Dovepress

  year unknowncited by this paper

• Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study

  2024cites this paper
• Case report: Atomoxetine improves chronic pain with comorbid post-traumatic stress disorder and attention deficit hyperactivity disorder

  2023cites this paper
• Dopamine transporter (DAT1) gene in combat veterans with PTSD: A case-control study.

  2021cites this paper
• Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice

  2013cites this paper